Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 9:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lung Preservation Clear all
Completed Not applicable Interventional Results available

International Randomized Study of the TransMedics Organ Care System (OCS Lung) for Lung Preservation and Transplantation

NCT01630434
View directory record Official record
Conditions
Lung Preservation
Interventions
OCS Lung, Cold flush and storage
Device
Lead sponsor
TransMedics
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 9, 2026, 9:06 AM EDT
Withdrawn Not applicable Interventional

Rivet PVS Therapy in Group 2 PH-HFpEF

NCT05205265
View directory record Official record
Conditions
Heart Failure, Pulmonary Hypertension
Interventions
Rivet Shunt
Device
Lead sponsor
NXT Biomedical
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • Rochester, Minnesota • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 2, 2024 · Synced Sep 9, 2026, 9:06 AM EDT
Withdrawn Not applicable Interventional

Cold Oxygen Lung Preservation and Ventilation With the "Angel Cooler"

NCT06286319
View directory record Official record
Conditions
Lung Diseases
Interventions
Angel Cooler
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Not applicable Interventional Results available

Extending Preservation and Assessment Time of Donor Lungs Using the Toronto EVLP System™ at a Dedicated EVLP Facility

NCT02234128
View directory record Official record
Conditions
Lung Disease
Interventions
Toronto EVLP System™
Device
Lead sponsor
Lung Bioengineering Inc.
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Jacksonville, Florida • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction

NCT01932606
View directory record Official record
Conditions
Heart Disease, Heart Failure With Preserved Ejection Fraction, Exercise Intolerance, Pulmonary Hypertension
Interventions
Nitrite, Saline Placebo for Nitrite
Drug
Lead sponsor
Barry Borlaug
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

NCT03541603
View directory record Official record
Conditions
Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
Interventions
Levosimendan, Matching Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 2 Interventional

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

NCT04945460
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Sotatercept 0.3 mg/kg, Placebo, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
Drug
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years to 85 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
56
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction

NCT02980068
View directory record Official record
Conditions
Pulmonary; Hypertension, Heart Failure, Preserved Ejection Fraction
Interventions
15N Nitrate, 14N Nitrate
Drug
Lead sponsor
Gladwin, Mark, MD
Individual
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients

NCT03624010
View directory record Official record
Conditions
Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction, Heart Failure With Normal Ejection Fraction
Interventions
Levosimendan
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
9
States / cities
Stanford, California • Chicago, Illinois • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Not applicable Interventional

Planned Semi-Elective Lung Transplantation Using 10C Cold Static Preservation

NCT04568694
View directory record Official record
Conditions
Pulmonary Disease
Interventions
Delayed Lung Transplantation, Conventional Lung Transplantation
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 9, 2026, 9:06 AM EDT
Terminated Not applicable Interventional Results available

Assessment of Pulmonary Congestion During Cardiac Hemodynamic Stress Testing

NCT04019613
View directory record Official record
Conditions
Dyspnea, Heart Failure With Preserved Ejection Fraction
Interventions
Lung ultrasound
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Sep 9, 2026, 9:06 AM EDT
Recruiting Phase 2 Interventional

Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases

NCT07130786
View directory record Official record
Conditions
Seizures, Primary Motor Cortex, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Adult, Brain Metastases From Extra-cranial Solid Tumors
Interventions
Levetiracetam (Keppra)
Drug
Lead sponsor
Ayal A. Aizer, MD
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 9, 2026, 9:06 AM EDT
Terminated Phase 3 Interventional Results available

Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF

NCT03043651
View directory record Official record
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
Oral treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

NCT03015402
View directory record Official record
Conditions
Pulmonary Hypertension Secondary, Heart Failure
Interventions
Sodium Nitrite, Placebo Oral Capsule
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

NCT03153111
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Macitentan, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 9, 2026, 9:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

HS235 Study in Obese Participants With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT07123779
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions
HS235, Placebo
Biological · Other
Lead sponsor
35Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 9, 2026, 9:06 AM EDT
Active, not recruiting Not applicable Interventional

10°C vs 4°C Lung Preservation RCT

NCT05898776
View directory record Official record
Conditions
Lung Transplant, Organ Preservation
Interventions
Lung transplantation after 10°C donor lung preservation, Lung transplantation after standard ice cooler donor lung preservation
Device
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years to 80 Years
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Phoenix, Arizona • San Francisco, California • Coral Gables, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 9, 2026, 9:06 AM EDT
Terminated Phase 1 Interventional

Study of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

NCT06581159
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Pulmonary Hypertension
Interventions
HS135, Placebo
Biological · Other
Lead sponsor
35Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Phoenix, Arizona • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 9, 2026, 9:06 AM EDT
Terminated Phase 4 Interventional Results available

Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure

NCT02053246
View directory record Official record
Conditions
Pulmonary Hypertension, Diastolic Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions
Nebivolol
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Sep 9, 2026, 9:06 AM EDT
Recruiting Not applicable Interventional

A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

NCT07214376
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases, Cardiovascular Diseases, Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
Interventions
Pulmonary Artery Denervation (PADN), Sham procedure control
Device
Lead sponsor
Pulnovo Medical, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
6
States / cities
Tucson, Arizona • Houma, Louisiana • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 3 Interventional Results available

Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial

NCT02885636
View directory record Official record
Conditions
Congestive Heart Failure, Heart Failure, Left-Sided, Left-Sided Heart Failure
Interventions
Albuterol, Saline placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 2 Interventional

Metformin for Pulmonary Hypertension HFpEF

NCT03629340
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure
Interventions
Metformin, Placebo oral capsule
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
San Francisco, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting

NCT01529502
View directory record Official record
Conditions
Blood Transfusion, Endothelial Physiopathology, Nitric Oxide, Pulmonary Hypertension
Interventions
Red blood Cells auto-transfusion, Inhaled Nitric Oxide (iNO) administration
Procedure · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Sep 9, 2026, 9:06 AM EDT
Terminated Phase 2 Interventional Results available

A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

NCT03714815
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
Interventions
macitentan 10 mg
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
11
States / cities
Littleton, Colorado • Chicago, Illinois • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 9, 2026, 9:06 AM EDT